Literature DB >> 15893270

Feasibility report for retreatment of locally recurrent head-and-neck cancers by combined brachy-chemotherapy using frameless image-guided 3D interstitial brachytherapy.

Robert C Krempien1, Christian Grehn, Claudia Haag, Anika Straulino, Frank W Hensley, Bibiana Kotrikova, Christof Hofele, Juergen Debus, Wolfgang Harms.   

Abstract

PURPOSE: Brachytherapy re-irradiation may offer an alternative re-treatment of recurrent head-and-neck cancer even after previous full dose radiation therapy. The purposes of this study were to determine the feasibility and accuracy of frameless image-guided interstitial needle implantation. METHODS AND MATERIALS: Between January 2000 and March 2003, 14 patients with biopsy-proven locally recurrent head-and-neck-cancer were retreated after previous full dose irradiation with combined external beam-brachytherapy with concomitant chemotherapy. Brachytherapy needle implantation was virtually planned taking into account the surrounding risk structures. Needles were implanted using an adapted frameless navigation system. Chemoradiotherapy was followed by 2-4 courses of chemotherapy every fourth week starting 4 weeks after the end of brachytherapy.
RESULTS: The 1- and 2-year local control rates were 78% and 57%, respectively. Local control was obtained in 8/14 patients. The actuarial 1- and 2-year survival rates were 83% and 64%, respectively. The median survival was 28 months after a median follow-up of 21 months (range, 8-53). Six weeks after brachytherapy, 1 patient developed localized soft tissue necrosis which did not require surgical intervention. No additional grade III or IV late toxicity was seen after re-irradiation. Mean deviation of image-guided needle implantation was 3.4 mm for each needle (SD, 1.9 mm; range, 0.5-14 mm). The mean deviation of all needles of an implant was 4.3 mm (range, 2.3-8.6 mm).
CONCLUSIONS: These data demonstrate that pulsed-dose-rate brachytherapy in combination with sequential chemotherapy is effective and safe in re-irradiation of locally recurrent oropharyngeal carcinomas and can be offered to patients with curative intent. Image guidance allows virtual planning and navigated implantation of brachytherapy needles with regard to optimized needle distribution and risk structures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893270     DOI: 10.1016/j.brachy.2005.02.001

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  6 in total

Review 1.  A review of the clinical experience in pulsed dose rate brachytherapy.

Authors:  Brian V Balgobind; Kees Koedooder; Diego Ordoñez Zúñiga; Raquel Dávila Fajardo; Coen R N Rasch; Bradley R Pieters
Journal:  Br J Radiol       Date:  2015-08-20       Impact factor: 3.039

2.  Brachytherapy in head and neck malignancies: Indian Brachytherapy Society (IBS) recommendations and guidelines.

Authors:  Rajendra Bhalavat; Ashwini Budrukkar; Sarbani Ghosh Laskar; Dayanand Sharma; Ashutosh Mukherji; Manish Chandra; Umesh Mahantshetty; Vibhay Pareek; Pratibha Bauskar; Sonali Saraf
Journal:  J Contemp Brachytherapy       Date:  2020-10-30

3.  CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers.

Authors:  Yu L Jiang; Na Meng; Jun J Wang; Ping Jiang; Hui Sh Yuan; Chen Liu; Ang Qu; Rui J Yang
Journal:  Radiat Oncol       Date:  2010-07-30       Impact factor: 3.481

Review 4.  Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.

Authors:  György Kovács
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

5.  An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy.

Authors:  Lihong Zhu; Yuliang Jiang; Junjie Wang; Weiqiang Ran; Huishu Yuan; Chen Liu; Ang Qu; Ruijie Yang
Journal:  World J Surg Oncol       Date:  2013-03-08       Impact factor: 2.754

Review 6.  (125)I Seed Permanent Implantation as a Palliative Treatment for Stage III and IV Hypopharyngeal Carcinoma.

Authors:  Lei Li; Jie Yang; Xiaojiang Li; Xiaoli Wang; Yanxin Ren; Jimin Fei; Yan Xi; Ruimei Sun; Jing Ma
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-07-21       Impact factor: 3.372

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.